article thumbnail

California Legislature Takes Another Swing at Private Equity Participation in Healthcare

JD Supra: Mergers

Last fall, private equity and hedge fund investors were given a reprieve from the prospect of increased oversight of healthcare transactions when California Governor Gavin Newsom unexpectedly vetoed Assembly Bill 3129 (AB 3129). By: Husch Blackwell LLP

article thumbnail

Eyes on the exit: Selling PE portfolio companies in complex markets

JD Supra: Mergers

By: White & Case LLP

Portfolio 171
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What the new private sale process regime means for private equity investors

JD Supra: Mergers

If you are a private equity investor considering potential P2P acquisitions after receiving initial soundings from management teams, then this new regime should be helpful in enabling early stage talks to happen in private. The UK Takeover Panel (the Panel) has published a new framework for private sale processes.

article thumbnail

A Sharper Focus: Exploring VC Side Letters

JD Supra: Mergers

A side letter in the venture capital sector is an agreement between an investor and the company it is investing in that entitles the investor to certain contractual rights, which supplement and are in addition to other rights specifically provided to the investor as a holder of equity securities under the companys governance documents the documents (..)

article thumbnail

Antitrust scrutiny of private equity deals intensifies

JD Supra: Mergers

Traditionally, private equity firms were seen as benign investors from an antitrust perspective. This is changing. In the past 12 months, PE-funded acquisitions have faced progressively more rigorous scrutiny by antitrust authorities. By: Allen & Overy LLP

article thumbnail

Institutional Investor Newsletter: 2024 End-of-Year Roundup

JD Supra: Mergers

A recent trend in continuation vehicles involves traditional private equity sponsors serving as the “lead investor” in lieu of, or in addition to, more traditional secondary buyers and institutional investors. By: DLA Piper

Investors 171
article thumbnail

2024 Healthcare Private Equity Outlook & Trends

JD Supra: Mergers

As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector. W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity.